Product Description
ALDA-341 is being developed by Stanford University for the treatment of Submandibular Gland Tumor and Parotid Gland Tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04296266?term=ALDA-341&draw=1&rank=1)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Stanford University
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04296266 |
IRB-32994 | P1 |
Completed |
Oncology Unspecified |
2017-12-18 |
2020-03-12 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|